13 citations
,
May 2011 in “Bioorganic & Medicinal Chemistry” Changing the 6-position on benzopyran molecules affects insulin release, with some compounds showing strong inhibitory effects.
42 citations
,
August 2012 in “Psychoneuroendocrinology” Finasteride reduces certain behaviors caused by D1-like receptor agonists but not by D2-like receptor agonists in mice.
82 citations
,
February 1989 in “The Journal of clinical endocrinology and metabolism/Journal of clinical endocrinology & metabolism” A three-month treatment with a GnRH agonist significantly lowered androgen levels and 5α-reductase activity in men with benign prostatic hyperplasia.
34 citations
,
June 2015 in “Journal of cardiovascular pharmacology and therapeutics” Direct vasodilators and sympatholytic agents are still useful for certain conditions despite being less common due to side effects and newer drugs.
2 citations
,
September 1992 in “Steroids” New A-homo-B, 19-dinor steroids showed strong antiandrogenic activity without affecting the enzyme 5α-reductase or androgen receptor binding.
October 2024 in “Scientific Reports” OXTR agonists may promote hair growth and be effective for treating hair loss.
36 citations
,
August 2011 in “Experimental Dermatology” Eccrine sweat gland's clear cells likely cause excessive sweating in hyperhidrosis.
12 citations
,
June 2019 in “Psychoneuroendocrinology” Allopregnanolone is needed for certain brain processing issues caused by D1 dopamine receptor activation.
80 citations
,
December 1996 in “Pain” Disruption of glycinergic circuits increases pain sensitivity, suggesting new pain treatment options.
Combining dutasteride or finasteride with an α1 blocker is more effective for managing BPH than using either alone.
47 citations
,
November 1982 in “Journal of Cardiovascular Pharmacology” Nitrendipine and nifedipine effectively block muscle contractions, while papaverine relaxes them and minoxidil needs high amounts to work.
37 citations
,
October 2006 in “Steroids” New sulfur-containing steroid analogs show promise for more targeted medical treatments.
December 2025 in “Naunyn-Schmiedeberg s Archives of Pharmacology” Agomelatine may help reduce benign prostatic hyperplasia by blocking certain inflammatory pathways.
6 citations
,
April 2004 in “Journal of Enzyme Inhibition and Medicinal Chemistry” New progesterone-based compounds can block male hormones.
10 citations
,
March 2023 in “Journal of Chemistry” New compounds show promise for treating benign prostate hyperplasia with fewer side effects.
4 citations
,
January 1998 in “Heterocycles” Researchers made two new compounds that could be used for medicine.
1 citations
,
December 2011 in “Arzneimittelforschung” CB-03-04 shows promise as a treatment for prostate issues due to its strong anti-androgen effects.
66 citations
,
January 2008 in “Pharmacology Biochemistry and Behavior” AC-5216 reduces anxiety in mice through neurosteroids affecting GABAA receptors.
186 citations
,
December 2011 in “Molecules” Three specific 4-azasteroid-2-oximes showed strong enzyme inhibition, but less than finasteride.
1 citations
,
January 2013 Bimatoprost treats glaucoma and promotes hair growth, with potential for more medical uses.
52 citations
,
January 2005 in “PubMed” Alpha-blockers are the most effective and widely used treatment for lower urinary tract symptoms, with minimal side effects.
May 1981 in “Inpharma (Balgowlah)” Medroxyprogesterone acetate improved sleep apnea symptoms in some obese patients.
27 citations
,
January 1984 in “Pharmacology & Therapeutics” Antiandrogens have important biological effects, but more research is needed to understand them fully and compare their effectiveness and side effects to other treatments.
February 2026 in “The Journal of Sexual Medicine” GnRH agonists can help manage recurrent priapism in sickle cell patients, but long-term safety is unclear.
May 2017 in “DOAJ (DOAJ: Directory of Open Access Journals)” Using GnRHa agonists helps diagnose and treat ovarian hyperthecosis when surgery isn't possible.
59 citations
,
August 2021 in “Frontiers in Endocrinology” GLP-1 receptor agonists, like Dulaglutide, Liraglutide, and Semaglutide, have potential benefits beyond the pancreas, including neuroprotection, pain suppression, cardiovascular protection, obesity management, and cancer treatment, but there are concerns about pancreatitis and pancreatic cancer risks.
129 citations
,
January 2004 in “Journal of medicinal chemistry” Researchers developed new compounds that target the androgen receptor effectively with fewer side effects.
1 citations
,
October 2005 in “Experimental and Clinical Endocrinology & Diabetes” Allopregnanolone and opioids together reduce stress hormone responses during pregnancy.
17 citations
,
January 2015 in “MedChemComm” New treatments for prostate cancer are less toxic and show promise, but more research is needed to enhance their effectiveness and reduce side effects.
22 citations
,
September 2002 in “Der Urologe” Alpha1-blockers effectively improve urinary symptoms in BPH, with alfuzosin and tamsulosin having fewer side effects.